BONE BIOLOGICS CORPORATION
Income Statement
| Line Item | Aug 2026 | Jun 2026 | May 2026 | Mar 2026 | Feb 2026 | Dec 2025 | Nov 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $308.7K | — | $141.6K | — | — | — | $187.8K |
| SG&A Expense | — | $499.4K | — | $663.5K | — | — | — | $527.5K |
| Operating Income | — | $-808.1K | — | $-805.1K | — | — | — | $-715.3K |
| Operating Margin | — | — | — | — | — | — | — | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | — | $-773.7K | — | $-766.0K | — | — | — | $-666.7K |
| Net Margin | — | — | — | — | — | — | — | — |
| EPS (Basic) | — | $-0.43 | — | $-0.43 | — | — | — | $-0.07 |
| EPS (Diluted) | — | $-0.43 | — | $-0.43 | — | — | — | $-0.07 |
| Shares Outstanding (Basic) | 2.8M | 1.8M | 1.8M | 1.8M | 1.8M | 1.8M | 9.0M | 9.0M |
| Shares Outstanding (Diluted) | 2.8M | 1.8M | 1.8M | 1.8M | 1.8M | 1.8M | 9.0M | 9.0M |
| Dividends Per Share | — | — | — | — | — | — | — | — |